UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

GSK estimates that around 60% of the 300,000-plus severe SLE patients in the US suffer from lupus nephritis each year, and a quarter of those develop end-stage renal disease.

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

Lupus eritematoso sistemico disseminato e malattia mista del tessuto connettivo (aumentato rischio di meningite asettica, vedere paragrafo 4.8). Uso concomitante di altri farmaci vasocostrittori usati ...

Dopo il grande successo della prima edizione, con tutti gli appuntamenti sold out, la Pinacoteca Agnelli e Distretto Cinema presentano per il secondo anno consecutivo "Cinema sulla Pista 500". Dal ...